Parameters of Oxidative and Inflammatory Status in a Three-Month Observation of Patients with Acute Myocardial Infarction Undergoing Coronary Angioplasty—A Preliminary Study
Abstract
:1. Introduction
2. Patients and Methods
2.1. Study Population
2.2. Statistical Analyses
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- World Health Organization: Cardiovascular Diseases (CVDs), Version Current: 17 May 2017. Available online: http://www.who.int/mediacentre/factsheets/fs317/en/ (accessed on 5 May 2019).
- Piepoli, M.F.; Hoes, A.W.; Agewall, S.; Albus, C.; Brotons, C.; Catapano, A.L.; Cooney, M.T.; Corra, U.; Cosyns, B.; Deaton, C.; et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2016, 37, 2315–2381. [Google Scholar] [CrossRef] [PubMed]
- Cervantes, G.K.; Llanas-Cornejo, D.; Husi, H. CVD and oxidative stress. J. Clin. Med. 2017, 6, 22. [Google Scholar] [CrossRef] [PubMed]
- Lopez-Candales, A.; Hernández Burgos, P.M.; Hernandez-Suarez, D.F.; Harris, D. Linking Chronic inflammation with cardiovascular disease: From normal aging to the metabolic syndrome. J. Nat. Sci. 2017, 3, e341. [Google Scholar] [PubMed]
- Montazerifar, F.; Karajibani, M.; Gilani, S.M.; Bolouri, A.; Hashemi, M.; Dashipour, A. Study of prooxidant-antioxidant balance and some risk factors of coronary artery disease. Res. Cardiovasc. Med. 2018, 7, 69–73. [Google Scholar] [CrossRef]
- Kelly, F.; Fussell, J. Role of oxidative stress in cardiovascular disease outcomes following exposure to ambient air pollution. Free Radic. Biol. Med. 2017, 110, 345–367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Żurawska-Płaksej, E.; Grzebyk, E.; Marciniak, D.; Szymańska-Chabowska, A.; Piwowar, A. Oxidatively modified forms of albumin in patients with risk factors of metabolic syndrome. J. Endocrinol. Invest. 2014, 37, 819–827. [Google Scholar] [Green Version]
- Ridker, P. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ. Res. 2016, 118, 145–156. [Google Scholar] [CrossRef] [PubMed]
- Adukauskienė, D.; Čiginskienė, A.; Adukauskaitė, A.; Pentiokinienė, D.; Šlapikas, R.; Čeponienė, I. Clinical relevance of high sensitivity C-reactive protein in cardiology. Medicina (Kaunas) 2016, 52, 1–10. [Google Scholar] [CrossRef]
- Ulla, M.; Pizzolato, E.; Lucchiari, M.; Loiacono, M.; Soardo, F.; Forno, D.; Morello, F.; Lupia, E.; Moiraghi, C.; Mengozzi, G.; et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: A multicenter prospective study. Crit. Care 2013, 17, R168. [Google Scholar] [CrossRef]
- Caglar, F.N.T.; Isiksacan, N.; Biyik, I.; Opan, S.; Cebe, H.; Akturk, I.F. Presepsin (sCD14-ST): Could it be a novel marker for the diagnosis of ST elevation myocardial infarction? Arch. Med. Sci. Atheroscler. Dis. 2017, 2, e3–e8. [Google Scholar] [CrossRef]
- Popov, D.; Plyushch, M.; Ovseenko, S.; Abramyan, M.; Podshchekoldina, O.; Yaroustovsky, M. Prognostic value of sCD14-ST (presepsin) in cardiac surgery. Kardiochir. Torakochirurgia Pol. 2015, 12, 30–36. [Google Scholar] [PubMed]
- Wang, Z.; Tang, W.W.; Buffa, J.A.; Fu, X.; Britt, E.B.; Koeth, R.A.; Levison, B.S.; Fan, Y.; Wu, Y.; Hazen, S.L. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur. Heart J. 2014, 35, 904–910. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, T.; Heaney, L.M.; Jones, D.J.; Ng, L.L. Trimethylamine N-oxide and risk stratification after acute myocardial infarction. Clin. Chem. 2017, 63, 420–428. [Google Scholar] [CrossRef] [PubMed]
- Higashi, Y.; Sukhanov, S.; Anwar, A.; Shai, S.Y.; Delafontaine, P. IGF-1, oxidative stress and atheroprotection. Trends Endocrinal. Metab. 2010, 21, 245–254. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ho, J.E.; Lyass, A.; Courchesne, P.; Chen, G.; Liu, C.; Yin, X.; Hwang, S.J.; Massaro, J.M.; Larson, M.G.; Levy, D. Protein biomarkers of cardiovascular disease and mortality in the community. J. Am. Heart Assoc. 2018, 7, e008108. [Google Scholar] [CrossRef] [PubMed]
- Kobza, J.; Geremek, M. Explaining the decrease in deaths from cardiovascular disease in Poland. The top-down risk assessment approach, from policy to health impact. Postepy Hig. Med. Doswiadczalnej 2016, 70, 295–304. [Google Scholar] [CrossRef]
- Rodrigo, R.; Libuy, M.; Feliú, F.; Hasson, D. Oxidative stress-related biomarkers in essential hypertension and ischemia-reperfusion myocardial damage. Dis. Markers 2013, 35, 773–790. [Google Scholar] [CrossRef]
- Roffi, M.; Patrono, C.; Collet, J.-P.; Mueller, C.; Valgimigli, M.; Andreotti, F.; Bax, J.J.; Borger, M.A.; Brotons, C.; Chew, D.P.; et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Kardiol. Pol. 2015, 73, 1207–1294. [Google Scholar] [CrossRef] [Green Version]
- Ibanez, B.; James, S.; Agewall, S.; Antunes, M.J.; Bucciarelli-Ducci, C.; Bueno, H.; Caforio, A.L.; Crea, F.; Goudevenos, J.A.; Halvorsen, S.; et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Kardiol. Pol. 2018, 76, 229–313. [Google Scholar] [CrossRef]
- Winther, J.R.; Thorpe, C. Quantification of thiols and disulfides. Biochim. Biophys. Acta 2014, 1840, 838–846. [Google Scholar] [CrossRef]
- Piwowar, A.; Knapik-Kordecka, M.; Warwas, M. Markers of oxidative protein damage in plasma and urine of type 2 diabetic patients. Br. J. Biomed. Sci. 2009, 66, 194–199. [Google Scholar] [CrossRef] [PubMed]
- Piwowar, A.; Knapik-Kordecka, M.; Warwas, M. Ischemia-modified albumin level in type 2 diabetes mellitus—Preliminary report. Dis. Markers 2008, 24, 311–317. [Google Scholar] [CrossRef] [PubMed]
- Re, R.; Pellegrini, N.; Proteggente, A.; Pannala, A.; Yang, M.; Rice-Evans, C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic. Biol. Med. 1999, 26, 1231–1237. [Google Scholar] [CrossRef]
- Pinnell, A.E.; Northam, B.E. New automated dye-binding method for serum albumin determination with bromcresol purple. Clin. Chem. 1978, 24, 80–86. [Google Scholar] [PubMed]
- Means, G.; End, C.; Kaul, P. Management of percutaneous coronary intervention complications. Curr. Treat. Options Cardiovasc. Med. 2017, 19, 25. [Google Scholar] [CrossRef] [PubMed]
- Kumar, A.A.; Kumar, P.G.; Swami, A.; Dinker, Y. Evaluation of changes in perfusion defect and left ventricular systolic function using Tc-99m tetrofosmin single photon emission computed tomography over 3 month period in patients of acute myocardial infarction undergoing primary angioplasty. Nucl. Med. Rev. Cent. East Eur. 2018, 21, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Wu, J.; Xia, S.; Kalionis, B.; Wan, W.; Sun, T. The role of oxidative stress and inflammation in cardiovascular aging. Biomed. Res. Int. 2014, 2014, 615312. [Google Scholar] [CrossRef] [PubMed]
- Liu, Z.; Zhou, T.; Ziegler, A.C.; Dimitrion, P.; Zuo, L. Oxidative stress in neurodegenerative diseases: From molecular mechanisms to clinical applications. Oxid. Med. Cell Longev. 2017, 2017, 2525967. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.J.; Kim, E.H.; Hahm, K.B. Oxidative stress in inflammation-based gastrointestinal tract diseases: Challenges and opportunities. J. Gastroenterol. Hepatol. 2012, 27, 1004–1010. [Google Scholar] [CrossRef]
- Krata, N.; Zagożdżon, R.; Foroncewicz, B.; Mucha, K. Oxidative stress in kidney diseases: The cause or the consequence? Arch. Immunol. Ther. Exp. (Warsz) 2018, 66, 211–220. [Google Scholar] [CrossRef]
- Knapik-Kordecka, M.; Piwowar, A.; Warwas, M. Disturbances of oxidative-antioxidative balance and atherosclerotic risk factors and vascular complications in patients with diabetes type 2. Wiad. Lek. 2007, 60, 329–334. (In Polish) [Google Scholar]
- Skvarilova, M.; Bulava, A.; Stejskal, D.; Adamovska, S.; Bartek, J. Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed. Pap. 2005, 149, 83–87. [Google Scholar] [CrossRef]
- Knapik-Kordecka, M.; Piwowar, A.; Żurawska-Płaksej, E.; Warwas, M. Ischemia modified albumin—Specific marker in cardiological diagnostics? Wiad. Lek. 2008, 61, 263–268. [Google Scholar] [PubMed]
- Li, X.S.; Obeid, S.; Klingenberg, R.; Gencer, B.; Mach, F.; Räber, L.; Windecker, S.; Rodondi, N.; Nanchen, D.; Muller, O.; et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: A prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur. Heart J. 2017, 38, 814–824. [Google Scholar] [CrossRef] [PubMed]
- Le Bras, A. Targeting the gut to protect the heart. Nat. Rev. Cardiol. 2018, 15, 581. [Google Scholar] [CrossRef]
- Parenica, J.; Jarkovsky, J.; Malaska, J.; Mebazaa, A.; Gottwaldova, J.; Helanova, K.; Litzman, J.; Dastych, M.; Tomandl, J.; Spinar, J.; et al. Infectious complications and immune/inflammatory response in cardiogenic shock patients: A prospective observational study. Shock 2017, 47, 165–174. [Google Scholar] [CrossRef]
- Saito, J.; Hashiba, E.; Mikami, A.; Kudo, T.; Niwa, H.; Hirota, K. Pilot study of changes in presepsin concentrations compared with changes in procalcitonin and C-reactive protein concentration after cardiovascular surgery. J. Cardiothorac. Vasc. Anesth. 2017, 31, 1262–1267. [Google Scholar] [CrossRef]
- Handke, J.; Scholz, A.S.; Gillmann, H.J.; Janssen, H.; Dehne, S.; Arens, C.; Kummer, L.; Uhle, F.; Weigand, M.A.; Motsch, J.; et al. Elevated presepsin is associated with perioperative major adverse coardiovascular and cerebrovascular complications in elevated-risk patients undergoing noncardiac surgery. Anesth. Analg. 2018, 128, 1344–1353. [Google Scholar] [CrossRef]
- Biyik, I.; Caglar, F.N.T.; Isiksacan, N.; Kocamaz, N.; Kasapoglu, P.; Gedikbasi, A.; Akturk, F. Serum presepsin levels are not elevated in patients with controlled hypertension. Int. J. Hypertens. 2018, 8, 8954718. [Google Scholar] [CrossRef]
- Ezzat, V.A.; Duncan, E.R.; Wheatcroft, S.B.; Kearney, M.T. The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes. Metab. 2008, 10, 198–211. [Google Scholar] [CrossRef]
- Yamaguchi, H.; Komamura, K.; Choraku, M.; Hirono, A.; Takamori, N.; Tamura, K.; Akaike, M.; Azuma, H. Impact of serum insulin-like growth factor-1 on early prognosis in acute myocardial infarction. Intern. Med. 2008, 47, 819–825. [Google Scholar] [CrossRef] [PubMed]
- Westermeier, F.; Bustamante, M.; Pavez, M.; García, L.; Chiong, M.; Ocaranza, M.P.; Lavandero, S. Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9). Pharmacol. Res. 2015, 101, 41–55. [Google Scholar] [CrossRef] [PubMed]
- Ukinc, K.; Eminagaoglu, S.; Ersoz, H.O.; Erem, C.; Karahan, C.; Hacihasanoglu, A.B.; Kocak, M. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: Ischemia-modified albumin. Endocrine 2009, 36, 425–432. [Google Scholar] [CrossRef] [PubMed]
Parameter (Unit) | Patients (n = 30) | Controls (n = 30) | Statistical Significance of Differences [p-Value] |
---|---|---|---|
Age (years) | 63 (54–75) | 59.5 (56–63) | 0.065 |
Male sex (n) | 21 | 19 | 0.58 |
BMI (kg/m2) | 27.1 (24.4–31.8) | 25.05 (22.7–28.1) | 0.057 |
SBP (mmHg) | 120 (117–130) | 130 (120–138) | 0.104 |
DBP (mmHg) | 72 (70–80) | 82 (75–87) | 0.051 |
WBC (109/L) | 8.68 (7.63–11.06) | 5.65 (4.70–6.20) | <0.001 |
hsCRP (mg/L) | 3.65 (2.26–9.90) | 1.54 (0.84–2.96) | 0.001 |
Glucose (mmol/L) | 6.0 (5.4–7.0) | 5.2 (5.0–5.5) | <0.001 |
Cholesterol (mmol/L) | 5.4 (4.3–6.3) | 5.9 (5.2–6.6) | 0.075 |
TG (mmol/L) | 1.51 (0.90–2.27) | 1.11 (0.80–1.46) | 0.025 |
HDL (mmol/L) | 1.16 (0.98–1.34) | 1.47 (1.21–1.65) | 0.002 |
LDL (mmol/L) | 3.38 (2.42–4.16) | 3.49 (2.92–4.21) | 0.53 |
Creatinine (µmol/L) | 76.1 (62.8–92.1) | 74.3 (64.6–90.2) | 0.65 |
Troponin I (µg/L | 7.1 (2.37–28.24) | NA | |
LV mass (g) | 315.5 (261–417) | NA | |
EF (%) | 60 (35–65) | NA | |
Presence of DM (n) | 6 | 0 | 0.031 |
Smoking habit (n) | 13 | 9 | 0.423 |
Parameter (Unit) | Patients | Controls | Statistical Significance of Differences [p-Value] | |||
---|---|---|---|---|---|---|
T0 | T3 | C | T0 vs. T3 | T0 vs. C | T3 vs. C | |
IMA (ABSU/g) | 40.5 (34.5–51.8) | 45.8 (39.8–57.3) | 41.1 (38.6–49.1) | 0.33 | 1.00 | 0.94 |
AOPP (μmol/L) | 226 (106–389) | 274 (180–391) | 147 (130–183) | 0.44 | 0.18 | 0.002 |
SH groups (mmol/L) | 0.41 (0.35–0.43) | 0.41 (0.23–0.46) | 0.52 (0.45–0.57) | 1.00 | <0.001 | <0.001 |
TAS (μmol/L) | 17.2 (15.6–17.9) | 16.6 (15.7–17.5) | 16.3 (15.8–16.9) | 1.00 | 0.11 | 0.54 |
TMAO (μmol/L) | 1.16 (0.92–1.24) | 1.22 (0.78–1.87) | 1.00 (0.84–2.96) | 0.93 | 0.38 | 0.033 |
IGF-1 (ng/mL) | 129 (84–176) | 148 (103–195) | 184 (145–235) | 1.00 | 0.030 | 0.24 |
Insulin (μU/mL) | 13.4 (10.6–29.8) | 16.0 (8.5–32.2) | 10.0 (7.2–13.2) | 1.00 | 0.044 | 0.026 |
hsCRP (mg/L) | 3.65 (2.26–9.90) | 1.31 (0.54–3.57) | 1.54 (0.84–2.96) | <0.001 | 0.005 | 1.00 |
PSP (mg/L) | 2.39 (2.25–2.83) | 2.55 (2.20–2.79) | 2.89 (2.67–3.44) | 1.00 | 0.008 | 0.020 |
Parameter (Unit) | T0 | T3 | EF < 50% | EF ≥ 50% | ||||
---|---|---|---|---|---|---|---|---|
EF < 50% | EF ≥ 50% | p | EF < 50% | EF ≥ 50% | p | T0 vs. T3 | T0 vs. T3 | |
n = 10 | n = 20 | n = 10 | n = 20 | n = 10 | n = 20 | |||
IMA (ABSU/g) | 52.0 (42.5–80.3) | 37.6 (32.0–46.6) | 0.007 | 57.3 (42.5–80.3) | 46.3 (40.0–51.9) | 0.344 | 0.799 | 0.030 |
AOPP (μmol/L) | 105.3 (78.9–125.6) | 286.6 (181.1–400.5) | 0.015 | 283.2 (141.1–315.1) | 266.6 (181.4–397.0) | 0.982 | 0.017 | 0.708 |
SH groups (mmol/L) | 0.41 (0.34–0.45) | 0.43 (037–0.46) | 0.552 | 0.42 (0.20–0.50) | 0.39 (0.26–0.46) | 0.982 | 0.508 | 0.433 |
TAS (μmol/L) | 17.5 (17.0–17.8) | 16.3 (15.3–18.1) | 0.379 | 17.1 (16.4–17.8) | 16.5 (15.3–17.9) | 0.135 | 0.386 | 0.550 |
TMAO (μmol/L) | 1.13 (0.92–1.38) | 1.22 (0.81–1.27) | 0.758 | 1.74 (1.17–3.10) | 1.03 (0.61–1.71) | 0.031 | 0.093 | 0.970 |
IGF-1 (ng/mL) | 107.4 (55.9–151.2) | 154.2 (95.2–261.0) | 0.056 | 117.4 (77.6–180.1) | 153.9 (132.2–213.3) | 0.209 | 0.047 | 0.526 |
Insulin (μU/mL) | 13.4 (11.2–18.3) | 13.9 (10.5–36.4) | 0.644 | 18.7 (8.5–29.8) | 18.0 (9.8–35.1) | 0.947 | 0.169 | 0.970 |
hsCRP (mg/L) | 11.00 (2.90–29.00) | 3.17 (1.20–7.55) | 0.045 | 1.68 (0.59–2.19) | 1.18 (0.52–3.63) 2.38 (2.30–2.79) | 0.741 | 0.012 | 0.015 |
PSP (mg/L) | 2.41 (1.89–3.43) | 2.38 (2.30–2.79) | 0.982 | 2.21 (1.95–2.54) | 2.59 (2.15–2.77) | 0.159 | 0.284 | 0.794 |
Variables | r and p-Values |
---|---|
T0 | |
IMA vs. IGF-1 | r = −0.376, p = 0.041 |
IMA vs. hsCRP | r = 0.466, p = 0.009 |
TAS vs. AOPP | r = −0.373, p = 0.042 |
TAS vs. SH groups | r = 0.409, p = 0.025 |
TAS vs. IGF | r = −0.375, p = 0.041 |
TMAO vs. hsCRP | r = 0.371, p = 0.044 |
TMAO vs. PSP | r = 0.381, p = 0.038 |
TMAO vs. insulin | r = 0.374, p = 0.042 |
T3 | |
TMAO vs. glucose | r = 0.374, p = 0.042 |
C | |
PSP vs. hsCRP | r = 0.356, p = 0.039 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Żurawska-Płaksej, E.; Płaczkowska, S.; Pawlik-Sobecka, L.; Czapor-Irzabek, H.; Stachurska, A.; Mysiak, A.; Sebzda, T.; Gburek, J.; Piwowar, A. Parameters of Oxidative and Inflammatory Status in a Three-Month Observation of Patients with Acute Myocardial Infarction Undergoing Coronary Angioplasty—A Preliminary Study. Medicina 2019, 55, 585. https://doi.org/10.3390/medicina55090585
Żurawska-Płaksej E, Płaczkowska S, Pawlik-Sobecka L, Czapor-Irzabek H, Stachurska A, Mysiak A, Sebzda T, Gburek J, Piwowar A. Parameters of Oxidative and Inflammatory Status in a Three-Month Observation of Patients with Acute Myocardial Infarction Undergoing Coronary Angioplasty—A Preliminary Study. Medicina. 2019; 55(9):585. https://doi.org/10.3390/medicina55090585
Chicago/Turabian StyleŻurawska-Płaksej, Ewa, Sylwia Płaczkowska, Lilla Pawlik-Sobecka, Hanna Czapor-Irzabek, Aneta Stachurska, Andrzej Mysiak, Tadeusz Sebzda, Jakub Gburek, and Agnieszka Piwowar. 2019. "Parameters of Oxidative and Inflammatory Status in a Three-Month Observation of Patients with Acute Myocardial Infarction Undergoing Coronary Angioplasty—A Preliminary Study" Medicina 55, no. 9: 585. https://doi.org/10.3390/medicina55090585